Here’s a good summary on psychedelics, along with potential benefits and risks.
Read more5-MeO-DMT Update!
Going On a Retreat? Consider this.
The Spirit Pharmacist discusses 9 questions to consider before going on a psychedelic retreat.
Read morePodcast on Psychedelics
Albert Garcia-Romeu, a researcher at John’s Hopkins University, joins Dr. Sanjay Gupta to talk about how psychedelics can alleviate mental suffering and what the path forward might look like.
Read moreVideo on Psychedelics
Can psychedelics cure? Psychedelics are unlocking new ways to treat conditions like addiction and depression. Click to watch!
Read morePsilocybin Mushrooms and Bipolar Disorder
A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder.
The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms.
Read moreThe Importance of Indigenous Knowledge
This can’t be emphasized enough: Various indigenous cultures found, used, and promoted plant-based psychedelics for human wellness and spiritual development for thousands of years, in almost every place where humans lived on the planet.
Read morePsychedelic Insights and Delusions
"Aha” moments in psychedelic therapy can offer unique insight and perspective. But some insights are false and others may ring true.
Read morePodcast: Dr. Andrew Weil Talks Psychedelics
Check out this podcast from Psychedelics Today~~ with New York Times best-selling author, pioneer in the field of integrative medicine, and overall legend in the health and wellness space: Andrew Weil, M.D.
Read morePsychedelics and Traumatic Brain Injury
MDMA-Assisted Therapy and PTSD
Here’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color